Over the last few years, significant improvements in the management of asthma and COPD have been made, owing to new drugs, strategies and to the development of the nonpharmacologic treatment of COPD. Nevertheless, there are still many unmet needs in the treatment of these diseases.Join us at SMi's 12th annual Asthma & COPD taking place on the 11th - 12th April 2016 in London. This event will explore innovative asthma and COPD drug development programmes, directives and procedures which have been put in place to reduce the enormous suffering from lung disease and its high mortality.Ewan Walters, Medical Director, Teva UK Peter Daley-Yates, Director Clinical Pharmacology, GSKAndy Kenwright, Senior Statistical Scientist, Roche PharmaJan Olof Svensson, Principal Scientist, AstraZenecaRoland Kolbeck, Senior Director, MedImmuneNayna Govind, Director for the Development of Generic Inhalation Products, Dr. Reddy's LaboratoriesKonstantinos Kostikas, Medical Director Respiratory, Novartis